d(GC) - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online)
of the protooncogene c-kit in peripheral
blood mononuclear cells of patients who
have mastocytosis with an associated
hematologic disorder. Proc Natl Acad Sci
U S A, 92: 10560-4.
90. Kimura, A., Nakata, Y., Katoh, O., and
Hyodo, H. (1997). c-kit Point mutation in
patients with myeloproliferative disorders.
Leuk Lymphoma, 25: 281-7.
91. Corless, C.L., Fletcher, J.A., and Heinrich,
M.C. (2004). Biology of gastrointestinal
stromal tumors. J Clin Oncol, 22: 3813-25.
92. Maleddu, A., Pantaleo, M.A., Nannini, M.
and Biasco, G. (2011). The role of
mutational analysis of KIT and PDGFRA in
gastrointestinal stromal tumors in a clinical
setting. Journal of Translational Medicine,
9: 75-82.
93. Heinrich, M.C., Corless, C.L., Demetri,
G.D., Blanke, C.D., von Mehren, M.,
Joensuu, H., McGreevey, L.S., Chen, C.J.,
Van den Abbeele, A.D., Druker, B.J., Kiese,
B., Eisenberg, B., Roberts, P.J., Singer, S.,
Fletcher, C.D., Silberman, S., Dimitrijevic,
S., and Fletcher, J.A. (2003). Kinase
mutations and imatinib response in patients
with metastatic gastrointestinal stromal
tumor. J Clin Oncol, 21: 4342-9.
94. Demetri, G.D., von Mehren, M., Blanke,
C.D., Van den Abbeele, A.D., Eisenberg,
B., Roberts, P.J., Heinrich, M.C., Tuveson,
D.A., Singer, S., Janicek, M., Fletcher, J.A.,
Silverman, S.G., Silberman, S.L.,
Capdeville, R., Kiese, B., Peng, B.,
Dimitrijevic, S., Druker, B.J., Corless, C.,
Fletcher, C.D., and Joensuu, H. (2002).
Efficacy and safety of imatinib mesylate in
advanced gastrointestinal stromal tumors.
N Engl J Med, 347: 472-80.
95. Verweij, J., Casali, P.G., Zalcberg, J.,
LeCesne, A., Reichardt, P., Blay, J.Y., Issels,
R., van Oosterom, A., Hogendoorn, P.C.,
Van Glabbeke, M., Bertulli, R., and Judson,
I. (2004). Progression-free survival in
Rebecca E. Smith and Juan Miguel Pascale
142
96.
gastrointestinal stromal tumours with highdose
imatinib: randomised trial. Lancet,
364: 1127-34.
Agaram, N.P., Besmer, P., Wong, G.C.,
Guo, T., Socci, N.D., Maki, R.G., DeSantis,
D., Brennan, M.F., Singer, S., DeMatteo,
R.P., and Antonescu, C.R. (2007).
Pathologic and molecular heterogeneity in
imatinib-stable or imatinib-responsive
gastrointestinal stromal tumors. Clin
Cancer Res, 13: 170-181.
97. Heinrich, M.C., Corless, C.L., Blanke, C.D.,
Demetri, G.D., Joensuu, H., Roberts, P.J.,
Eisenberg, B.L., von Mehren, M., Fletcher,
C.D., Sandau, K., McDougall, K., Ou, W.B.,
Chen, C.J., and Fletcher, J.A. (2006).
Molecular correlates of imatinib resistance
in gastrointestinal stromal tumors. J Clin
Oncol, 24: 4764-74.
98. Gounder, M.M. and Maki, R.G. (2011).
Molecular basis for primary and secondary
tyrosine kinase inhibitor resistance in
gastrointestinal stromal tumor. Cancer
Chemother Pharmacol, 67 Suppl 1: S25-
43.
99. Mendoza, Y., Singh, C., Mewa, J.C.,
Fonseca, E., Smith, R. and Pascale, J.M.
(2011). The beginning of personalized
medicine in Panama: molecular and
pathological characteristics of
Gastrointestinal Stromal Tumors (GIST)
from Archival Paraffin-embedded Tissue.
Oncology Letters, 2: 941-947.
100. Pao, W., Miller, V., Zakowski, M., Doherty,
J., Politi, K., Sarkaria, I., Singh, B., Heelan,
R., Rusch, V., Fulton, L., Mardis, E., Kupfer,
D., Wilson, R., Kris, M., and Varmus, H.
(2004). EGF receptor gene mutations are
common in lung cancers from “never
smokers” and are associated with
sensitivity of tumors to gefitinib and erlotinib.
Proc Natl Acad Sci U S A, 101: 13306-11.
101. Derecskei, K., Moldvay, J., Bogos, K., and
Timar, J. (2006). Protocol modifications